{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:38:38Z","timestamp":1794335918227,"version":"4.9.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nucl. Med."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To evaluate the effectiveness of positron emission tomography (PET) with [\n                      <jats:sup>11<\/jats:sup>\n                      C]-Pittsburgh Compound-B ([\n                      <jats:sup>11<\/jats:sup>\n                      C]PiB) for detecting transthyretin amyloid (ATTR) cardiomyopathy in patients with transthyretin gene (\n                      <jats:italic>TTR<\/jats:italic>\n                      ) variants associated with reduced bone scintigraphy sensitivity, and its ability to detect brain involvement in hereditary transthyretin amyloidosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This prospective case series included four hereditary ATTR amyloidosis patients with\n                      <jats:italic>TTR<\/jats:italic>\n                      variants associated with reduced bone scintigraphy sensitivity, and two patients with positive bone scintigraphy (one hereditary ATTR and one wild-type ATTR amyloidosis patient). All patients underwent diagnostic work-up at the Groningen Amyloidosis Centre of Expertise between April 2024 and March 2025, including [\n                      <jats:sup>11<\/jats:sup>\n                      C]PiB PET\/CT. Cardiac and brain [\n                      <jats:sup>11<\/jats:sup>\n                      C]PiB uptake were assessed visually. Target-to-background ratios (TBRs) and cortical SUV ratios were calculated. TBR \u22651.09 was considered positive for ATTR cardiomyopathy and SUV ratios \u22650.7 was considered positive for brain involvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cardiac [\n                      <jats:sup>11<\/jats:sup>\n                      C]PiB uptake was observed in three of four hereditary ATTR amyloidosis patients despite negative bone scintigraphy. In one of four patients, there was visually equivocal radiotracer uptake, but elevated TBRs did indicate ATTR cardiomyopathy. Conversely, both hereditary ATTR and wild-type ATTR amyloidosis patients with a positive bone scintigraphy had negative or inconclusive [\n                      <jats:sup>11<\/jats:sup>\n                      C]PiB PET results. Brain uptake was observed in two asymptomatic patients, while no uptake was seen in two patients with suspected brain involvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>11<\/jats:sup>\n                      C]PiB PET could be an effective tool for detecting ATTR cardiomyopathy in patients with\n                      <jats:italic>TTR<\/jats:italic>\n                      variants associated with reduced bone scintigraphy sensitivity. However, its utility for detecting brain involvement in symptomatic hereditary ATTR patients remains uncertain.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnume.2026.1747625","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:46:26Z","timestamp":1770623186000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Pittsburgh compound B positron emission tomography detects cardiomyopathy in hereditary transthyretin amyloidosis patients with negative bone scintigraphy: a pilot study"],"prefix":"10.3389","volume":"6","author":[{"given":"Hendrea S. A.","family":"Tingen","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen","place":["Groningen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles N.","family":"Stormezand","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen","place":["Groningen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"van Snick","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen","place":["Groningen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqi","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen","place":["Groningen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Van Der Zwaag","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen","place":["Groningen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marish","family":"Oerlemans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Utrecht","place":["Utrecht, Netherlands"]},{"name":"Member of the European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen","place":["Groningen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouke P. C.","family":"Hazenberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen","place":["Groningen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Luurtsema","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen","place":["Groningen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans L. A.","family":"Nienhuis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen","place":["Groningen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riemer H. J. A.","family":"Slart","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen","place":["Groningen, Netherlands"]},{"name":"Biomedical Photonic Imaging Group, Faculty of Science and Technology, University of Twente","place":["Enschede, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.rdc.2013.02.012","article-title":"Amyloidosis: a clinical overview","volume":"39","author":"Hazenberg","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","article-title":"Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies","volume":"9","author":"Koike","year":"2020","journal-title":"Neurol Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/13506129.2024.2435573","article-title":"Pathogenesis, manifestations, diagnosis, and management of CNS complications in hereditary ATTR amyloidosis","volume":"32","author":"Sekijima","year":"2025","journal-title":"Amyloid"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s12350-019-01950-2","article-title":"Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation","volume":"28","author":"Minutoli","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/ejhf.3339","article-title":"Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis","volume":"26","author":"Muller","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/joim.12585","article-title":"One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition","volume":"281","author":"Suhr","year":"2017","journal-title":"J Intern Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","article-title":"(99\u2005m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis","volume":"121","author":"Pilebro","year":"2016","journal-title":"Ups J Med Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","article-title":"Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis","volume":"13","author":"Musumeci","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"B11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12350-016-0638-5","article-title":"Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR)","volume":"25","author":"Pilebro","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/13506129.2020.1798223","article-title":"Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11C-Pittsburgh compound B PET imaging","volume":"27","author":"Takasone","year":"2020","journal-title":"Amyloid"},{"key":"B13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/13506129.2020.1760237","article-title":"Quantification of cardiac amyloid with [18F]flutemetamol in patients with V30M hereditary transthyretin amyloidosis","volume":"27","author":"M\u00f6ckelind","year":"2020","journal-title":"Amyloid"},{"key":"B14","doi-asserted-by":"publisher","first-page":"816636","DOI":"10.3389\/fneur.2022.816636","article-title":"Cerebellar and cerebral amyloid visualized by [18F]flutemetamol PET in long-term hereditary V30M (p.V50M) transthyretin amyloidosis survivors","volume":"13","author":"Uneus","year":"2022","journal-title":"Front Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/13506129.2022.2128331","article-title":"Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis","volume":"30","author":"Takahashi","year":"2023","journal-title":"Amyloid"},{"key":"B16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1212\/WNL.0000000000003001","article-title":"Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis","volume":"87","author":"Sekijima","year":"2016","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","article-title":"Diagnostic accuracy of [11C]PIB positron emission tomography for detection of cardiac amyloidosis","volume":"13","author":"Rosengren","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"B18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hbm.10123","article-title":"Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe","volume":"19","author":"Hammers","year":"2003","journal-title":"Hum Brain Mapp"},{"key":"B19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.amjcard.2017.09.029","article-title":"Frequency of and prognostic significance of cardiac involvement at presentation in hereditary transthyretin-derived amyloidosis and the value of N-terminal pro-B-type natriuretic peptide","volume":"121","author":"Klaassen","year":"2018","journal-title":"Am J Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1007\/s00259-025-07157-7","article-title":"Enhanced diagnostic and prognostic assessment of cardiac amyloidosis using combined 11C-PiB PET\/CT and 99mTc-DPD scintigraphy","volume":"52","author":"Hong","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2967\/jnumed.111.102053","article-title":"In Vivo visualization of amyloid deposits in the heart with 11 C-PIB and PET","volume":"54","author":"Antoni","year":"2013","journal-title":"J Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s00259-017-3814-1","article-title":"Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging","volume":"45","author":"Ezawa","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B24","doi-asserted-by":"publisher","first-page":"830572","DOI":"10.3389\/fcvm.2022.830572","article-title":"Diagnostic value of 11C-PIB PET\/MR in cardiac amyloidosis","volume":"9","author":"Bi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","article-title":"Cardiac amyloid detection by PET\/CT imaging of iodine (124I) evuzamitide (124I-p5+14): a phase 1\/2 study","volume":"16","author":"Wall","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"B26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/path.2411","article-title":"Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis","volume":"216","author":"Ihse","year":"2008","journal-title":"J Pathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.rcl.2023.01.009","article-title":"Cerebral amyloid angiopathy","volume":"61","author":"Szidonya","year":"2023","journal-title":"Radiol Clin North Am"},{"key":"B29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s00259-016-3591-2","article-title":"Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer\u2019s disease neuroimaging initiative (J-ADNI) multicenter study","volume":"44","author":"Yamane","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.14283\/jpad.2021.15","article-title":"The epidemiology of Alzheimer\u2019s disease modifiable risk factors and prevention","volume":"8","author":"Zhang","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","article-title":"Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis","volume":"313","author":"Ossenkoppele","year":"2015","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2967\/jnumed.116.184028","article-title":"Total-Body PET: maximizing sensitivity to create new opportunities for clinical research and patient care","volume":"59","author":"Cherry","year":"2018","journal-title":"J Nucl Med"}],"container-title":["Frontiers in Nuclear Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2026.1747625\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:13:13Z","timestamp":1772453593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2026.1747625\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":32,"alternative-id":["10.3389\/fnume.2026.1747625"],"URL":"https:\/\/doi.org\/10.3389\/fnume.2026.1747625","relation":{},"ISSN":["2673-8880"],"issn-type":[{"value":"2673-8880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"1747625"}}